Gelastic seizure

Ibogaine By David Dardashti Offers Expanded Treatment Options

Retrieved on: 
Dimanche, avril 21, 2024
Gelastic seizure, Environment, Aftercare, Patient, Dolphin, Swimming, Hope, Growth, Pharmaceutical industry

MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce an expanded treatment program providing greater support and more comprehensive care options to those suffering from addiction.

Key Points: 
  • MIAMI, April 21, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti is proud to announce an expanded treatment program providing greater support and more comprehensive care options to those suffering from addiction.
  • To ensure every patient receives the best possible treatment, the team at Ibogaine By David Dardashti is now offering a more extensive treatment option.
  • This includes providing the patient with a free reflection treatment several months after the initial ibogaine treatment to help the person discover the growth that the ibogaine treatment has provided them.
  • “At Ibogaine By David Dardashti we are committed to providing our patients with the very best care,” said David Dardashti, founder of Ibogaine By David Dardashti.

The Incretin Impact: A New Era in Metabolic Disease and Obesity Drug Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Mardi, avril 16, 2024
University, Incretin, DSM-IV codes, All India Mahila Congress, Diabetes, PET, Entrepreneurship, Drug discovery, Obesity, University of Copenhagen, Senior, Magnetic resonance imaging, MRI, Drug development, Chemistry, Gelastic seizure

TORONTO , April 16, 2024 /PRNewswire-PRWeb/ -- With the demonstrated efficacy and approvals of recent incretin-based therapies for the treatment of diabetes and obesity, one might think this is it for incretins. But really, it is just the beginning — given the possibilities for new combinations, different formulations and more indications throughout metabolic diseases and beyond.

Key Points: 
  • Attendees will learn why the future of incretin drug development will likely expand with different combinations, formulations and disease indications.
  • It is currently a very exciting time within drug development for incretins, but there is still a lot we do not know.
  • How can we better understand their effects and advance drug development in obesity and metabolic disease?
  • Register for this webinar today to learn about incretins, the current status of incretin drug development and the speakers' perspectives on the future of incretin drug development.

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Retrieved on: 
Jeudi, avril 4, 2024
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Gallium, Diagnosis, Radionuclide, Glomus tumor, Prostate cancer, USP, Half-life, Actinium-225, Partnership, Patient, Pharmacy, RLS, PET, Splenic infarction, Cancer, SDAX, Radiopharmaceutical, Investment, Cyclotron, ISO, Positron emission tomography, DSM-IV codes, Gelastic seizure, Medical imaging

Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.

Key Points: 
  • Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.
  • “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing.
  • This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals."
  • To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June.

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Retrieved on: 
Mardi, janvier 2, 2024
Blood pressure, Amnesia, Patient, Medical Subject Headings, Autopsy, Marketing, European Commission, Dementia, Agency, INN, Risk, Physician, ATC, Positron emission tomography, International, European, PET, Nausea, Nuclear medicine, Brain, Language, Gelastic seizure, Cancer, Flushing, Chronic pain, Radiation, Lewy body dementias, Amyloid, Select, Committee, Medicine, Diagnosis, Safety, Radiopharmaceutical, Risk management, Anatomy, Skin, IIA, Deficit spending, CHMP, Medical imaging

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Date of authorisation: 22/08/2014, Revision: 17, Status: Authorised

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID

Retrieved on: 
Jeudi, avril 13, 2023
Inflammation, COVID-19, Coronavirus Scientific Advisory Board, Research, COVID, Pharmacist, Patient, Mass, Protocol, Gelastic seizure, Microglia, DSM-IV codes, Hospital, SPMS, FDA, IND, Disease, Pharmaceutical industry, Brigham

The work is supported by foralumab’s well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.

Key Points: 
  • The work is supported by foralumab’s well-established role in de-activating microglia cells, a key component in the pathogenesis of this disease.
  • “I am excited to test intranasal foralumab in this medically important condition.
  • The use of PET Scans will allow us to determine if intranasal foralumab will decrease activated microglia in patients with Long COVID after 3 months of administration.
  • In essence, intranasal foralumab modulates activated microglia while returning effector T cells to a naïve state.9 If this finding is replicated in patients with Long COVID, I believe that foralumab could represent a novel treatment for this devasting condition.”